FORE Biotherapeutics today announced that the Company will participate at the following investor conferences:

• Wells Fargo 21^st Annual Healthcare Conference. The Company will attend and participate in one-on-one meetings on Tuesday, September 8.

• Morgan Stanley 24^th Annual Global Healthcare Conference. The Company will attend on Tuesday, September 15, and will provide a corporate presentation at 7:45 a.m. ET.

Management will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394 or PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1^st and 2^nd generation BRAF inhibitors. For more information, please visit www.fore.bio or follow us on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260901770867/en/